Novo Nordisk stock has pulled back sharply over the last three years, yet the company still screens as attractively valued on several checks. Recent news on obesity drug competition, U.S. pricing pressure and a failed cardiovascular trial has put the share price under pressure again, which makes the current valuation worth a closer look for investors.

• The share price has declined 46.1% over the past three years, which raises the question of whether sentiment has moved further than the fundamentals.
• Stronger long term expectations around the obesity drug portfolio can support valuation, while weaker U.S. sales and setbacks in cardiovascular drug development may limit what investors are willing to pay.
• Novo Nordisk currently scores 5 out of 6 on the broader valuation checks, which suggests the stock leans cheap on the measures used here.

The issue now is whether that valuation support is enough to offset the competitive and pricing risks that have dragged on Novo Nordisk shares in recent years.

Does Novo Nordisk Look Undervalued on Earnings?

The P/E ratio is a useful way to think about what you are paying for Novo Nordisk’s earnings today. It links the current share price directly to the profits the company is generating.

Novo Nordisk trades on a P/E of 11.7x, which is below both the pharmaceuticals industry average of 17.1x and a peer group that sits around 45.0x. A tailored fair P/E for Novo Nordisk, which reflects its margins, size and risk profile, is estimated at 25.2x. That is above the current multiple and indicates a discount versus what investors might typically pay for a business with similar characteristics.

Despite recent pressure on the stock after the ZEUS cardiovascular trial setback and concerns around U.S. obesity drug pricing, the current P/E still leaves Novo Nordisk trading at a discount to that fair multiple.

Overall, Novo Nordisk stock appears undervalued on a P/E basis compared with both its industry and an adjusted fair multiple.

The Novo Nordisk Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Novo Nordisk valuation puzzle leaves off and explain which combinations of future growth, margins and earnings would need to occur for the stock to be worth significantly more or less than today based on those assumptions. Each narrative links its number to a clear view on how Novo Nordisk's growth, profitability and key risks could change over time, which you can revisit as new information becomes available, and they are located on the company’s Community page.

One of the top community narratives on Novo Nordisk: 50% undervalued

"While sentiment is weak and valuation has compressed to roughly mid-teens forward earnings, Novo has added an important de-risking catalyst. Oral Wegovy has been FDA-approved and launched in the US…"

Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!

The Bottom Line

Novo Nordisk currently screens as undervalued on market multiples, with the P/E sitting below both sector peers and a tailored fair ratio. The key question is whether that discount reflects temporary concern around obesity drug competition and U.S. pricing, or a more durable reset in what investors are willing to pay for its earnings. From here, the crux is whether Novo Nordisk can defend margins and sustain demand in obesity treatments strongly enough for the market to re rate the stock closer to peer and fair multiples.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.